Evercore analyst Vijay Kumar maintains $GE HealthCare Technologies (GEHC.US)$ with a buy rating, and adjusts the target price from $96 to $102.
According to TipRanks data, the analyst has a success rate of 57.6% and a total average return of 5.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $GE HealthCare Technologies (GEHC.US)$'s main analysts recently are as follows:
In the MedTech sector, continued positive utilization trends are observed going into Q3, and the capital expenditure forecast for the coming year appears favorable. For life science tools, there is an anticipation of improved bioprocess trends in the latter half of the year. Nevertheless, discussions persist regarding the prospects for instruments and the potential impact of China's economic stimulation, especially considering the recent performance of stocks in this segment.
GE Healthcare was the recipient of favorable news when the FDA granted approval for Flurpiridaz, a novel myocardial perfusion imaging (MPI) positron emission tomography (PET) radiopharmaceutical. This product stands out as it is available as a pre-made 'individual dose,' a significant advantage over current on-site dose production methods. According to due diligence with physicians, there is a consensus that Flurpiridaz may offer notable clinical benefits over existing MPI radiopharmaceuticals. Additionally, a swift adoption by current U.S. cardiac PET centers is anticipated, and the availability of Flurpiridaz is expected to substantially widen the scope of U.S. cardiac PET procedures.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Evercore分析師Vijay Kumar維持$GE HealthCare Technologies (GEHC.US)$買入評級，並將目標價從96美元上調至102美元。
根據TipRanks數據顯示，該分析師近一年總勝率為57.6%，總平均回報率為5.6%。
此外，綜合報道，$GE HealthCare Technologies (GEHC.US)$近期主要分析師觀點如下：
在醫療技術領域，進入第三季度，利用率持續呈現積極趨勢，來年的資本支出預測似乎樂觀。在生命科學工具方面，預計下半年生物工藝趨勢將有所改善。儘管如此，關於工具前景和中國經濟刺激的潛在影響的討論仍在繼續，特別是考慮到該細分市場股票的近期表現。
美國食品藥品管理局批准了Flurpiridaz，這是一種新型心肌灌注成像（MPI）正電子發射斷層掃描（PET）放射性藥物，GE Healthcare受到了好消息。該產品之所以脫穎而出，是因爲它可以作爲預製的 「個人劑量」 提供，與目前的現場劑量生產方法相比，這是一個顯著的優勢。根據對醫生的盡職調查，人們一致認爲，與現有的MPI放射性藥物相比，Flurpiridaz可能具有顯著的臨床益處。此外，預計目前的美國心臟pET中心將迅速採用，預計Flurpiridaz的上市將大大擴大美國心臟pET手術的範圍。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
